Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Absci Corporation (Nasdaq: ABSI) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical and biotechnology company using generative AI and synthetic biology to design biologic therapeutics, Absci uses these filings to report on its financial condition, pipeline progress, capital markets activity, and key corporate events.
Investors can review Absci’s current reports on Form 8-K, which have recently covered topics such as quarterly financial results, updates on internal programs like ABS-201 and ABS-101, investor presentations, and material definitive agreements including underwritten equity offerings. These filings also confirm that Absci’s common stock is listed on The Nasdaq Global Select Market under the symbol ABSI.
In addition to 8-Ks, users can locate Absci’s annual reports on Form 10-K and quarterly reports on Form 10-Q through this page. Those reports typically include management’s discussion and analysis, audited or reviewed financial statements, and detailed information on the company’s Integrated Drug Creation platform, clinical-stage programs, risk factors, and liquidity. For a company like Absci, these periodic reports are central to understanding how it funds and advances its AI-designed antibody pipeline and partnered drug creation projects.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as changes in cash runway, updates to clinical development plans, or new collaboration agreements. Real-time updates from the SEC’s EDGAR system ensure that new Absci filings appear promptly, while access to insider transaction reports on Form 4, when filed, can help users monitor equity awards and trades by directors and officers.
By using this page, investors and researchers can efficiently navigate Absci’s regulatory history, compare successive filings, and place news releases about its generative AI platform and clinical programs in the context of the company’s formal SEC disclosures.
Absci Corp executive Zachariah Jonasson, the company’s CFO and CBO, reported a tax-related share disposition. On this Form 4/A, 17,496 shares of common stock were withheld by Absci at a price of $2.99 per share to satisfy tax obligations tied to vesting restricted stock units. After this withholding transaction, Jonasson directly owned 383,538 common shares. The footnote explains that this was not a discretionary trade by Jonasson but an automatic share withholding to cover taxes.
Absci Corp Chief Executive Officer Sean McClain reported a tax-related share disposition connected to vesting restricted stock units. The company withheld 26,761 shares of common stock at a price of $2.99 per share to satisfy withholding obligations, and McClain held 8,334,567 shares directly afterward. The filing specifies this was a tax-withholding event, not a discretionary trade.
Absci Corp director buys additional shares on the open market. Director Menelas N. Pangalos purchased 75,095 shares of Absci Corp common stock in an open-market transaction at a price of $2.74 per share. After this purchase, he directly owns 189,055 common shares.
Absci Corp director and CEO Sean McClain exercised stock options and had shares withheld for taxes. On February 23, 2026, he exercised options to purchase 396,399 shares of common stock at an exercise price of $1.21 per share before their March 3, 2026 expiration.
To cover the option exercise price and applicable tax withholding obligations, 267,008 shares of common stock were disposed of through share withholding, rather than an open-market sale, at $2.65 per share. After these transactions, McClain directly owned 8,463,958 shares of Absci common stock.
Absci Corp’s Chief Innovation Officer, Andreas Busch, reported an automatic share withholding related to equity compensation. On February 3, 2026, 1,469 shares of common stock were withheld by the company at $2.99 per share to satisfy tax obligations from vesting restricted stock units.
Following this tax-withholding event, Busch beneficially owns 322,703 shares of Absci common stock directly. According to the footnote, this transaction did not represent a discretionary trade or open-market sale by the insider.
Absci Corp’s Chief Executive Officer and director Sean McClain reported a transaction involving company common stock. On 02/02/2026, 26,761 shares at $2.99 per share were withheld by Absci to satisfy tax obligations tied to vesting restricted stock units, rather than being sold at his discretion. Following this withholding, McClain directly beneficially owned 8,334,567 common shares of Absci.
Absci Corp executive Jonasson Zachariah, the company’s CFO/CBO, reported a tax-related share withholding on February 2, 2026. Absci withheld 17,496 shares of common stock at $2.99 per share to cover tax obligations arising from the vesting of restricted stock units, which the filing states was not a discretionary trade. After this withholding, Zachariah directly beneficially owned 383,538 shares of Absci common stock.
Absci Corp officer Todd Bedrick reported an automatic share withholding related to equity compensation. On 02/02/2026, 3,659 shares of common stock at $2.99 per share were withheld by Absci to cover tax obligations from vesting restricted stock units. After this tax withholding, Bedrick directly beneficially owned 172,624 common shares. The footnote clarifies this was not a discretionary trade or open-market sale by the reporting person.
Absci Corporation reported that senior vice president and chief accounting officer Todd Bedrick received new equity awards on January 28, 2026. He was granted 15,000 shares of Common Stock in the form of restricted stock units at a price of $0, increasing his directly held Common Stock to 176,283 shares.
Bedrick was also granted a stock option for 59,400 shares of Common Stock at an exercise price of $2.94 per share, expiring on January 27, 2036. Both the RSUs and the option vest in three substantially equal annual installments starting on January 10, 2027, subject to his continuous service with Absci.
The Vanguard Group has filed a Schedule 13G reporting beneficial ownership of 7,910,205 shares of Absci Corp common stock, representing 5.26% of the class as of 12/31/2025.
Vanguard reports shared voting power over 996,166 shares and shared dispositive power over 7,910,205 shares, with no sole voting or dispositive power. The filing states these securities are held in the ordinary course of business and not for changing or influencing control of Absci. Vanguard notes an internal realignment effective 01/12/2026, after which certain subsidiaries may report beneficial ownership separately while continuing the same investment strategies.